首页> 外文会议>Annual Applied Science and Engineering Conference >Immunogenicity evaluation of recombinant fim-c salmonella typhi protein as typhoid vaccine candidate on wistar rat
【24h】

Immunogenicity evaluation of recombinant fim-c salmonella typhi protein as typhoid vaccine candidate on wistar rat

机译:重组FIM-C沙门氏菌Typhi蛋白作为Wistar大鼠伤寒疫苗候选的免疫原性评价

获取原文

摘要

Typhoid fever is a world health problem and often occurs in developing countries,including Indonesia.In a previous study,the UNJ Salmonella team successfully isolated,cloned,expressed,and purified inclusion bodies Fim-C S.typhi recombinant protein sized 31 Kilo Dalton(KDa).Furthermore,these proteins have been used as antigen in immunogenicity evaluation with ddY mice as test animals and give excellent results.This study aims to determine the immune response other of rodent test animals against Fim-C S.typhi recombinant protein as antigen.Immunogenicity evaluation was performed using male Wistar rats.That were divided into five test groups: Normal group,Control Group 1,Control Group 2,and Samples Group 1,Samples Group 2.The results of the ELISA analysis showed an increase in antibody titters produced by Wistar rats after subcutaneous immunized with Fim-C protein emulsified adjuvant or without adjuvant.The result of Western Blot showed the specific interaction between iinclusion bodies Fim-C S.typhi recombinant protein as antigen with anti-Fim-C S.typhi antibodies.It can be concluded that Fim-C S.typhi protein can be used as a potential vaccine candidate for typhoid disease.These results are expected to be an alternative in the discovery of new vaccines.
机译:伤寒是世界健康问题,经常发生在发展中国家,包括印度尼西亚。在以前的一项研究中,Unj Salmonella团队成功隔离,克隆,表达和纯化包涵体FIM-C S.Typhi重组蛋白大小31公里( KDA)。次蛋白质,这些蛋白质已被用作免疫原性评估中的抗原与DDY小鼠作为试验动物,并提供优异的结果。本研究旨在确定啮齿动物试验动物的免疫应答,针对FIM-C S.Typhi重组蛋白作为抗原的其他啮齿动物试验动物用雄性Wistar大鼠进行。用雄性Wistar大鼠进行。分为五个试验组:正常组,对照组1,对照组2和样品组1,样品组2. ELISA分析的结果显示抗体奶油用FIM-C蛋白质乳化佐剂或不佐剂的皮下免疫接种后的Wistar大鼠产生。Western印迹的结果显示Iinclusion体F之间的特异性相互作用IM-C s.typhi重组蛋白作为抗FIM-C s.typhi抗体的抗原。可以得出结论,FIM-C S.typhi蛋白可以用作伤寒疾病的潜在疫苗候选者。这些结果预期在发现新疫苗的替代方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号